These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Drug interactions of gliclazide and other sulfonylureas in protein binding in vitro and in hypoglycemic effect in rats. Fujii T; Nakamura K; Furukawa H; Watanabe M; Kuwashima J; Miyazaki H; Kawashima K; Kuzuya T Arzneimittelforschung; 1983; 33(11):1535-7. PubMed ID: 6686448 [TBL] [Abstract][Full Text] [Related]
48. Thyroid-blocking activity of chlorpropamide in a diabetic patient with hyperthyroidism. Tsou JY; Kotler M; Lavine RL Arch Intern Med; 1981 Apr; 141(5):690-1. PubMed ID: 7224756 [No Abstract] [Full Text] [Related]
49. Investigation of hypoglycemic properties of rectal suppositories with chlorpropamide. Kosior A Acta Pol Pharm; 2002; 59(2):109-13. PubMed ID: 12365601 [TBL] [Abstract][Full Text] [Related]
50. Experimental antihyperglycemic effect of diterpenoids of llareta Azorella compacta (Umbelliferae) Phil in rats. Fuentes NL; Sagua H; Morales G; Borquez J; San Martin A; Soto J; Loyola LA Phytother Res; 2005 Aug; 19(8):713-6. PubMed ID: 16177976 [TBL] [Abstract][Full Text] [Related]
51. Clinical evaluation of a new hypoglycemic sulfonylurea, tolazamide. A preliminary report on its chlorinated analogue, azepinamide. ABELOVE WA; ECHENIQUE R; HILLS AG Diabetes; 1962; 11():216-21. PubMed ID: 14036545 [No Abstract] [Full Text] [Related]
52. Potential antidiabetics. 7. N1-(beta-hydroxybenzylmethyl)-3-methyl-4-arylhydrazono-2-pyrazolin-5-ones and N1-(beta-hydroxybenzylmethyl)-3-methyl-4-arylazo-5-methyl- or -phenylpyrazoles. Garg HG; Prakash C J Med Chem; 1971 Feb; 14(2):175-6. PubMed ID: 5544413 [No Abstract] [Full Text] [Related]
53. [Apropos of the intolerance to alcoholic beverages of diabetics during chlorpropamide treatment: hypoglycemic effect of the drug administered together with ethanol]. FARINELLI A; FERSINI C; RIPA R; PIFFANELLI A Arcisp S Anna Ferrara; 1960; 13(Suppl 6)():1539-61. PubMed ID: 13698197 [No Abstract] [Full Text] [Related]
54. Plasma AVP after intravenous chlorpropamide. Huupponen R; Viinamäki O; Lammintausta R Int J Clin Pharmacol Ther Toxicol; 1981 Jan; 19(1):6-8. PubMed ID: 7203732 [TBL] [Abstract][Full Text] [Related]
55. [Effect of cyclamide, chlorcyclamide, chlorpropamide and butamide on the blood sugar level]. GENES SG; MAKAREVICH-GAL'PERIN LM; USHENKO SN Farmakol Toksikol; 1960; 23():535-9. PubMed ID: 13704350 [No Abstract] [Full Text] [Related]
56. [Hypoglycemic coma during chlorporpamide therapy]. Boman H Tidsskr Nor Laegeforen; 1966 Apr; 86(7):472-3. PubMed ID: 5913633 [No Abstract] [Full Text] [Related]
57. Surreptitious hypoglycemia secondary to tolazamide. Levy WJ; Sheeler LR South Med J; 1981 Jan; 74(1):63-4. PubMed ID: 7455744 [No Abstract] [Full Text] [Related]
59. Clinical trial with tolazamide, a new hypoglycemia agent; its potency compared to chlorpropamide. Quismorio FT; Villadolid LS; Egay LM; Wico AR; Llamas SP; Acurantes AI Acta Med Philipp; 1967; 3(4):261-5. PubMed ID: 6069635 [No Abstract] [Full Text] [Related]
60. Blood glucose and drug levels in normal fasting subjects following single oral doses of tolazamide and chlorpropamide. Novak E; Borden K; Vitti T; Hearron M Mich Med; 1969 Dec; 68(24):1243-5. PubMed ID: 4901022 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]